As of May 26, 2023, Evolus has been the subject of analysis by five experts over the past three months. These analysts have offered 12-month price targets, with an average target of $18.00. The consensus rating for the company is Buy, with a rating score of 2.80. This score is based on four buy ratings, one hold rating, and no sell ratings.
It is worth noting that the greater the number of bullish ratings, the more positive analysts are on the stock, while the greater the number of bearish ratings, the more negative they are. The average rating score for Evolus has increased by 13.59% from the previous average price target of $15.67.
According to analysts’ consensus price target of $16.00, Evolus has a forecasted upside of 89.1% from its current price. However, it is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders. Therefore, investors should always do their own research before making any investment decisions.
Evolus Inc. (EOLS) Stock Analysis: Market Capitalization Remains Steady Despite Low Trading Volume
On May 26, 2023, Evolus Inc. (EOLS) opened at 9.06 and fluctuated within a range of 8.92 to 9.14, with a low trading volume of only 338 shares. Despite this, EOLS’s market capitalization remained steady at $557.3 million. The company’s earnings growth in the last year was negative, at -41.12%, but has since bounced back with a positive earnings growth of +42.91% this year. EOLS’s P/E ratio was not available, but the price/sales ratio was 2.83, indicating that the stock may be undervalued compared to its sales. The price/book ratio was high at 29.77, which could suggest that the stock is overvalued compared to its book value. EOLS operates in the Health Technology sector and the Pharmaceuticals: Major industry and is headquartered in Newport Beach, California. The EPS forecast for the next quarter is -$0.22, but the annual revenue for the last year was $148.6 million, suggesting that the company may still have room for growth and improvement.
Evolus Inc (EOLS) Stock Outlook: Analysts Predict 101.57% Increase in Median Target Price
On May 26, 2023, Evolus Inc (EOLS) stock showed a promising outlook, with a median target price of $18.00, according to nine analysts offering 12-month price forecasts. The high estimate was $25.00, while the low estimate was $10.00. The median estimate represented a whopping 101.57% increase from the last price of $8.93. The current consensus among the nine polled investment analysts recommended buying EOLS stock, indicating a sustained bullish sentiment towards the company. Despite the current quarter’s lackluster performance, the overall outlook for EOLS stock was optimistic, with the company’s flagship product, Jeuveau, gaining traction in the market and plans to launch a new product in the second half of 2023. Investors were eagerly awaiting the company’s earnings report on August 02, 2023, to see if the company could turn things around in the upcoming quarter.
Discussion about this post